Adagene (ADAG) has released an update.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Adagene’s new clinical data, presented at the ESMO Congress, shows promising results for ADG126, a novel anti-CTLA-4 antibody, when used in combination with pembrolizumab for the treatment of metastatic microsatellite-stable colorectal cancer (MSS CRC). The treatment demonstrated an overall response rate of 24%, a median progression-free survival of 8.5 months, and an encouraging safety profile with low rates of severe treatment-related adverse events. This combination therapy offers a potential new treatment option for MSS CRC patients, including those with liver metastases.
For further insights into ADAG stock, check out TipRanks’ Stock Analysis page.